CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Staidson Beijing BioPharmaceutcls Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Staidson Beijing BioPharmaceutcls Co Ltd
No. 36 Jinghai Er Road
Phone: +86 1067875255p:+86 1067875255 BEIJING, BEJ  100176  China Ticker: 300204300204
Business Summary
Staidson Beijing BioPharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development (R&A), production and marketing of biological drugs. The drugs developed, produced and sold by the Company mainly include protein drugs, chemical drugs and other categories, and the treatment areas focus on infectious diseases, autoimmune diseases and nervous system diseases. The Company's R&D pipeline products include BDB-001, STSA-1002, STSA-1005, STSA-1002, STSA-1005, STSA-1201, STSA-1301, STSP-0601, STSG-0002, and others. The Company's marketed products are mainly innovative biological drugs Sutepsen and special varieties Shutaiqing and its series of products.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ZhiwenZhou 57 11/8/2022
Chief Financial Officer ShichengLi 41 8/9/2024 8/9/2024
Finance Director, General Manager ChaoWang 41 8/9/2024 8/9/2024
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 555 (As of 12/31/2023)
Outstanding Shares: 477,772,555 (As of 9/30/2024)
Shareholders: 31,965
Stock Exchange: SHE
Fax Number: +86 1067875255


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024